Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,406 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969136
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Not applicable Interventional

Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment

NCT01669200
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Medium Chain Triglyceride Oil, Placebo Oil
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

NCT02063230
View directory record Official record
Conditions
Solid Tumors
Interventions
Selumetinib 50mg, Selumetinib 25mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

NCT01641081
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of IL-11 in DDAVP Unresponsive

NCT00994929
View directory record Official record
Conditions
Hemophilia A, Von Willebrand Disease
Interventions
Neumega (Oprelvekin, Interleukin 11, IL-11)
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 31, 2026, 2:55 AM EDT
Active, not recruiting No phase listed Observational

Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury

NCT05092295
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
Head and Intraocular Trauma Tool, SCAT-5
Device · Diagnostic Test
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
13 Years to 45 Years
Enrollment
200 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Withdrawn Not applicable Interventional

Mag Con: Efficacy of Oral Mag. in Acute Concussion in Adolescents

NCT05065528
View directory record Official record
Conditions
Concussion, Mild, Traumatic Brain Injury, Mild
Interventions
Magnesium, Placebo
Dietary Supplement · Drug
Lead sponsor
Corewell Health South
Other
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 31, 2026, 2:55 AM EDT
Terminated Not applicable Interventional

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

NCT05569005
View directory record Official record
Conditions
COPD, Smoking, Tobacco Use
Interventions
THS use, Cigarette, Smoking Abstinence
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
35 Years to 65 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
81
States / cities
Brandon, Florida • Cape Coral, Florida • Clearwater, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

NCT05817045
View directory record Official record
Conditions
COVID-19
Interventions
RD-X19, Sham
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
40 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
48
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

NCT00744965
View directory record Official record
Conditions
Mild Gestational Diabetes
Interventions
Glyburide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 31, 2026, 2:55 AM EDT
Completed No phase listed Observational

Mild Pulmonary Function Changes With Transfusion

NCT00681954
View directory record Official record
Conditions
Transfusion Reactions
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

NCT01343966
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

NCT00089037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
methotrexate, sirolimus, tacrolimus
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2011 · Synced Oct 31, 2026, 2:55 AM EDT
Terminated Phase 2 Interventional

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

NCT04428775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALZT-OP1a (cromolyn)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Geniculate Artery Embolization for Treatment of Osteoarthritis

NCT04379700
View directory record Official record
Conditions
Osteoarthritis
Interventions
Transcatheter arterial embolization, Embozene™ Microspheres
Procedure · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 31, 2026, 2:55 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Detecting Probable Alzheimer's Disease From Speech Using Linguistical Analysis

NCT04041895
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Audio speech recording
Other
Lead sponsor
East Tennessee State University
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Not applicable Interventional

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

NCT04800120
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Taunton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Plasticity Using Stimulation and Habit: A Pilot Open-label rTMS Study for MCI

NCT04503096
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
High-dose accelerated rTMS
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 31, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Interventions
natural product combination-1 (NPC1)
Combination Product
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

NCT05205980
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Perturbation training
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
65 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Valdosta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Problem Adaptation Therapy for Mild Cognitive Impairment and Depression

NCT03043573
View directory record Official record
Conditions
Cognitive Impairment, Depression
Interventions
PATH-MCI, Supportive Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 31, 2026, 2:55 AM EDT